Form 4: Armata Pharmaceuticals Director Acquires Stock Options

Jules Haimovitz, a director of Armata Pharmaceuticals, acquired stock options exercisable for 54,343 shares of common stock on February 5, 2025.

Summary

• On February 5, 2025, Jules Haimovitz, a director of Armata Pharmaceuticals, acquired stock options for 54,343 shares of common stock.
• The exercise price of these options is $2.04.
• The options vest in two tranches: 50% on February 5, 2026, and the remaining 50% on February 5, 2027, contingent upon continuous service through each vesting date.
• The options expire on February 5, 2035.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative outlook.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their potential alignment with shareholder interests.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's success.

Key Dates

Keywords

stock options, director, Armata Pharmaceuticals, ARMP, insider trading, beneficial ownership